A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Trial details
- Registry ID
- NCT05456256
- Drugs studied
- Carboplatin, LP-300, Pemetrexed
TrialRedline tracks 1 clinical trial sponsored by Lantern Pharma Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256 | Carboplatin, LP-300, Pemetrexed | Recruiting | 2026-12Estimated |
Names as written in the registry records.
NCT05456256 · Lantern Pharma Inc.
Before: Dec 2025. After: Dec 2026.